Last mentioned: Mar 25, 2026
Target Commercialization
Anticipated EU launch for iopofosine I 131 treatment of WM.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
EMA Submission
Target window for filing the CMA for iopofosine I 131 in the European Union.
CLR 125 Data Readout
Expected early data from the Phase 1b study in Triple Negative Breast Cancer.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Annual Results Announcement
CEO James Caruso provides corporate updates and confirms regulatory timelines.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Phase II Completion
Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
Fiscal Year End
Cellectar concludes a year focused on pipeline execution and supply chain strengthening.
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Texas Governor Greg Abbott has launched a formal investigation into the safety and security of medical devices manufactured in China and used within the state's healthcare system. The move signals a growing trend of state-level scrutiny over international medical supply chains and potential vulnerabilities in critical healthcare infrastructure.
Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
This page surfaces every story mentioning U.S. Food and Drug Administration across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where U.S. Food and Drug Administration was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |